29 April 2017

HEALTH - FDA Targets Illegal Cancer Treatment Claims

It is a violation of the Federal Food, Drug and Cosmetic Act to market and sell products that claim to prevent, diagnose, treat, mitigate or cure diseases without first demonstrating to the FDA that they are safe and effective for their labeled uses.

This week the FDA sent warning letters to 14 US-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer.

The products are being marketed for human and/or pet use and mainly sold through websites and social media.

“Consumers should not use these or similar unproven products because they may be unsafe and could prevent a person from seeking an appropriate and potentially life-saving cancer diagnosis or treatment,” said Douglas W. Stearn, director of the Office of Enforcement and Import Operations in the FDA’s Office of Regulatory Affairs.

The illegally sold products cited in the warning letters include a variety of product types, such as pills, topical creams, ointments, oils, drops, syrups, teas and diagnostics (such as thermography devices).

The products make illegal, unproven claims regarding preventing, reversing or curing cancer; killing/inhibiting cancer cells or tumors; or other similar anti-cancer claims.

Companies receiving the warning letters are:
  • AIE Pharmaceuticals Ltd.
  • Amazing Sour Sop Inc.
  • BioStar Technology International, LLC
  • Caudill Seed & Warehouse Inc.
  • DoctorVicks.com
  • Everything Herbs
  • Hawk Doc Natural Salve, LLC
  • Healing Within Products & Services Inc.
  • LifeVantage Corporation
  • Nature’s Treasure Inc.
  • Oxygen Health Services, LLC
  • Sunstone Inc.
  • The Vibrant Health Store, LLC dba Dr. Christopher’s Herbs
  • The Vitamin C Foundation

It is important to consult with a veterinarian or physician before using any products for health care treatment.

The FDA encourages health care professionals and consumers to report adverse reactions associated with these or similar products to the agency’s MedWatch program.

No comments:

Post a Comment